{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T21:57:28Z","timestamp":1784152648913,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["diabetesresearchclinicalpractice.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.diabres.2015.12.003","type":"journal-article","created":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T22:21:13Z","timestamp":1452291673000},"page":"125-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: Results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide"],"prefix":"10.1016","volume":"113","author":[{"given":"Savvoula","family":"Savvidou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyparissia","family":"Karatzidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalliopi","family":"Tsakiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asterios","family":"Gagalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prodromos","family":"Hytiroglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Goulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.diabres.2015.12.003_bib0235","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diabres.2013.11.002","article-title":"Global estimates of diabetes prevalence in adults for 2013 and projections for 2035","volume":"103","author":"Guariguata","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.diabres.2015.12.003_bib0240","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clinthera.2007.01.015","article-title":"Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials","volume":"29","author":"Buse","year":"2007","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.diabres.2015.12.003_bib0245","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/193229680800200214","article-title":"Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes","volume":"2","author":"Nielsen","year":"2008","journal-title":"J Diabetes Sci Technol"},{"issue":"5","key":"10.1016\/j.diabres.2015.12.003_bib0250","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2337\/dc06-2247","article-title":"Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients","volume":"30","author":"Targher","year":"2007","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.diabres.2015.12.003_bib0255","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology","volume":"142","author":"Chalasani","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.diabres.2015.12.003_bib0260","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1464-5491.2011.03480.x","article-title":"Biomarkers for diabetes prediction, pathogenesis or pharmacotherapy guidance? Past, present and future possibilities","volume":"29","author":"Sattar","year":"2012","journal-title":"Diabet Med"},{"issue":"1","key":"10.1016\/j.diabres.2015.12.003_bib0265","doi-asserted-by":"crossref","first-page":"T37","DOI":"10.1530\/JOE-12-0278","article-title":"The role of adipokines in \u03b2-cell failure of type 2 diabetes","volume":"216","author":"Dunmore","year":"2013","journal-title":"J Endocrinol"},{"issue":"12","key":"10.1016\/j.diabres.2015.12.003_bib0270","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/j.1440-1681.2011.05606.x","article-title":"Hypoadiponectinaemia in diabetes mellitus type 2: molecular mechanisms and clinical significance","volume":"38","author":"Su","year":"2011","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"6","key":"10.1016\/j.diabres.2015.12.003_bib0275","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1002\/hep.26072","article-title":"Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause?","volume":"57","author":"van der Poorten","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.diabres.2015.12.003_bib0280","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.beem.2013.06.006","article-title":"Signaling mechanisms underlying the insulin-sensitizing effects of adiponectin","volume":"28","author":"Cheng","year":"2014","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.diabres.2015.12.003_bib0285","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11695-008-9678-5","article-title":"GLP-1 and adiponectin: effect of weight loss after dietary restriction and gastric bypass in morbidly obese patients with normal and abnormal glucose metabolism","volume":"19","author":"de Carvalho","year":"2009","journal-title":"Obes Surg"},{"issue":"4","key":"10.1016\/j.diabres.2015.12.003_bib0290","first-page":"167","article-title":"GLP-1 receptor agonists","volume":"18","author":"McDougall","year":"2011","journal-title":"Br J Cardiol"},{"key":"10.1016\/j.diabres.2015.12.003_bib0295","first-page":"706416","article-title":"Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus","volume":"2015","author":"Junnuchi","year":"2015","journal-title":"J Diabetes Res"},{"issue":"5","key":"10.1016\/j.diabres.2015.12.003_bib0300","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0006-2952(01)00924-8","article-title":"Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1","volume":"63","author":"Idris","year":"2002","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"10.1016\/j.diabres.2015.12.003_bib0305","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2169\/internalmedicine.52.8961","article-title":"Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus","volume":"52","author":"Suzuki","year":"2013","journal-title":"Intern Med"},{"issue":"12","key":"10.1016\/j.diabres.2015.12.003_bib0310","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/j.1464-5491.2012.03699.x","article-title":"Exenatide plus metformin compared with metformin alone on \u03b2-cell function in patients with type 2 diabetes","volume":"29","author":"Derosa","year":"2012","journal-title":"Diabet Med"},{"issue":"3","key":"10.1016\/j.diabres.2015.12.003_bib0315","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/1753-0407.12198","article-title":"Weight loss effect of glucagon-like peptide-1 mimetics on obese\/overweight adults without diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Zhang","year":"2015","journal-title":"J Diabetes"},{"issue":"9","key":"10.1016\/j.diabres.2015.12.003_bib0320","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/j.1478-3231.2011.02626.x","article-title":"Glucagon-like peptide 1 receptor and the liver","volume":"31","author":"Pedersen","year":"2011","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.diabres.2015.12.003_bib0325","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.21006","article-title":"Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice","volume":"43","author":"Ding","year":"2006","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.diabres.2015.12.003_bib0330","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.diabres.2015.12.003_bib0335","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1007\/s00125-011-2317-z","article-title":"Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial","volume":"54","author":"Samson","year":"2011","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.diabres.2015.12.003_bib0340","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1248\/bpb.b14-00505","article-title":"The glucagon-like peptide-1 analogue liraglutide inhibits oxidative stress and inflammatory response in the liver of rats with diet-induced non-alcoholic fatty liver disease","volume":"38","author":"Gao","year":"2015","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"10.1016\/j.diabres.2015.12.003_bib0345","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1185\/030079908X253870","article-title":"Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years","volume":"24","author":"Klonoff","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"10.1016\/j.diabres.2015.12.003_bib0350","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1478-3231.2011.02462.x","article-title":"Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis","volume":"31","author":"Svegliati-Baroni","year":"2011","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.diabres.2015.12.003_bib0355","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1478-3231.2006.01315.x","article-title":"Incretin mimetics as a novel therapeutic option for hepatic steatosis","volume":"26","author":"Tushuizen","year":"2006","journal-title":"Liver Int"},{"issue":"12","key":"10.1016\/j.diabres.2015.12.003_bib0360","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1038\/oby.2011.152","article-title":"Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes","volume":"19","author":"Sathyanarayana","year":"2011","journal-title":"Obesity (Silver Spring)"},{"issue":"9","key":"10.1016\/j.diabres.2015.12.003_bib0365","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1590\/S0004-27302013000900005","article-title":"Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease","volume":"57","author":"Fan","year":"2013","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"12","key":"10.1016\/j.diabres.2015.12.003_bib0370","doi-asserted-by":"crossref","first-page":"e50117","DOI":"10.1371\/journal.pone.0050117","article-title":"Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists","volume":"7","author":"Cuthbertson","year":"2012","journal-title":"PLOS ONE"},{"issue":"10","key":"10.1016\/j.diabres.2015.12.003_bib0375","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1463-1326.2007.00832.x","article-title":"Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels","volume":"10","author":"Li","year":"2008","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.diabres.2015.12.003_bib0380","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/liv.12120","article-title":"GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK","volume":"33","author":"Zhang","year":"2013","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.diabres.2015.12.003_bib0385","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.bbrc.2009.10.015","article-title":"Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression","volume":"390","author":"Kim Chung le","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.diabres.2015.12.003_bib0390","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.diabres.2015.12.003_bib0395","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0009-9120(01)00263-6","article-title":"The plasma parameter log (TG\/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL))","volume":"34","author":"Dobi\u00e1sov\u00e1","year":"2001","journal-title":"Clin Biochem"},{"key":"10.1016\/j.diabres.2015.12.003_bib0400","unstructured":"Quantikine. Human Adiponectin\/Acrp30 Immunoassay. [R&D Systems Website]. Available at: http:\/\/www.rndsystems.com\/pdf\/drp300.pdf."},{"key":"10.1016\/j.diabres.2015.12.003_bib0405","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","author":"Brunt","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.diabres.2015.12.003_bib0410","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Nonalcoholic steatohepatitis clinical research network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2015.12.003_bib0415","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/jhep.2003.50229","article-title":"Clinical and histological spectrum of non-alcoholic fatty liver disease associated with normal ALT values","volume":"37","author":"Mofrad","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2015.12.003_bib0420","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Non-alcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N Eng J Med"},{"issue":"6","key":"10.1016\/j.diabres.2015.12.003_bib0425","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.bpg.2004.06.021","article-title":"Non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis (NAFLD\/NASH): diagnosis and clinical course","volume":"18","author":"Cortez-Pinto","year":"2004","journal-title":"Best Pract Res Clin Gastrenterol"},{"key":"10.1016\/j.diabres.2015.12.003_bib0430","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00125-003-1074-z","article-title":"Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex","volume":"46","author":"Cnop","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2015.12.003_bib0435","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/hep.22063","article-title":"Low circulating levels of dehydroepiandrosterone in histologically advanced NAFLD","volume":"47","author":"Charlton","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2015.12.003_bib0440","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/hep.22372","article-title":"Does the hormone of eternal youth protect against NASH?","volume":"48","author":"Manco","year":"2008","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.diabres.2015.12.003_bib0445","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2337\/dc11-1434","article-title":"Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.diabres.2015.12.003_bib0450","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.diabet.2010.02.001","article-title":"Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity","volume":"36","author":"Preumont","year":"2010","journal-title":"Diabetes Metab"},{"issue":"8","key":"10.1016\/j.diabres.2015.12.003_bib0455","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.2337\/dc09-2361","article-title":"Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition","volume":"33","author":"Bunck","year":"2010","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2015.12.003_bib0460","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.diabres.2014.01.019","article-title":"Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with type 2 diabetes: a prospective study","volume":"104","author":"D\u00edaz-Soto","year":"2014","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822716000061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822716000061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T04:24:50Z","timestamp":1537071890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822716000061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":46,"alternative-id":["S0168822716000061"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2015.12.003","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: Results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2015.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}